4 Amendments of Daciana Octavia SÂRBU related to 2016/2057(INI)
Amendment 36 #
Motion for a resolution
Citation 7 a (new)
Citation 7 a (new)
- having regard to Directive 2001/83/EC and in particular Article 81 thereof;
Amendment 193 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Stresses that full transparency of the cost of development andresearch and development, including clinical trials is crucial in order to set a fair price;
Amendment 358 #
Motion for a resolution
Paragraph 16 a (new)
Paragraph 16 a (new)
16a. Points out that improved coordination between national HTAs could reduce the time taken for medicines to become available to patients;
Amendment 400 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Calls on the Commission to promote R&D driven by patients’ needs, while fostering social responsibility in the pharmaceutical sector, by setting up an EU public platform for R&D funded by contributions from profits made by the pharmaceutical industry through sales to public health systems; calls for full transparency on the costs of R&D;